Bristol-Myers Squibb (BASE:BMY) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BMY 주식 개요

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발굴, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 기업입니다.

BMY 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	4/6
과거 실적	0/6
재무 상태	3/6
배당금	5/6

보상

공정 가치 추정치보다 낮은 59% 에서 거래

수익은 매년 44.73% 증가할 것으로 예상됩니다.

위험 분석

부채비율이 높네요

5.88% 의 배당금은 수익으로 잘 충당되지 않습니다.

Bristol-Myers Squibb Company 경쟁사

GSK

LSE:GSK

UK£62.4b

Zoetis

NYSE:ZTS

US$79.1b

Merck KGaA

XTRA:MRK

€67.3b

Sanofi

ENXTPA:SAN

€112.4b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Bristol-Myers Squibb
과거 주가
현재 주가	US$18,739.00
52주 최고치	US$22,442.50
52주 최저치	US$10,600.00
베타	0.43
11개월 변경	10.08%
3개월 변경 사항	-2.71%
1년 변경 사항	71.58%
33년 변화	374.77%
5년 변화	2,551.15%
IPO 이후 변화	71,061.47%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BMY	AR Pharmaceuticals	AR 마켓
7D	1.1%	-0.1%	3.4%
1Y	71.6%	-28.2%	263.9%

수익률 대 산업: BMY 지난 1년 동안 -25.2 %를 반환한 AR Pharmaceuticals 산업을 초과했습니다.

수익률 대 시장: BMY 지난 1년 동안 257.2 %를 반환한 AR 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement	5.6%
Pharmaceuticals Industry Average Movement	4.5%
Market Average Movement	7.2%
10% most volatile stocks in AR Market	10.0%
10% least volatile stocks in AR Market	5.5%

안정적인 주가: BMY 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: BMY 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1887	34,100	Chris Boerner	www.bms.com

브리스톨-마이어스 스퀴브 컴퍼니는 전 세계에서 바이오 의약품을 발견, 개발, 허가, 제조, 마케팅, 유통 및 판매하는 회사입니다. 혈액학, 종양학, 심혈관계, 면역학, 섬유성 및 신경과학 질환을 위한 제품을 제공합니다. 주요 제품으로는 비판막성 심방세동 환자의 뇌졸중/전신색전증 위험 감소 및 심부정맥혈전증/폐색전증 치료를 위한 엘리퀴스, 방광, 혈액, CRC, 두경부암, RCC, 간암, 폐암, 흑색종, MPM, 위암 및 식도암 등 다양한 항암 적응증을 위한 옵디보 등이 있습니다; 다발성 골수종 치료제 포말리스트/이노비드, 활동성 류마티스 관절염 및 건선성 관절염 치료제 오렌시아, 필라델피아 염색체 양성 만성 골수성 백혈병 치료제 스프라이셀 등을 공급하고 있습니다.

Bristol-Myers Squibb Company 기본 사항 요약

Bristol-Myers Squibb 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BMY 기본 통계
시가총액	AR$76.73t
수익(TTM)	-AR$5.60t
수익(TTM)	AR$41.50t

1.8x

P/S 비율

-13.7x

P/E 비율

BMY 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BMY 손익 계산서(TTM)
수익	US$45.53b
수익 비용	US$10.92b
총 이익	US$34.62b
기타 비용	US$40.77b
수익	-US$6.15b

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

Jul 26, 2024

주당 순이익(EPS)	-3.03
총 마진	76.03%
순이익 마진	-13.50%
부채/자본 비율	336.7%

BMY 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

5.8%

현재 배당 수익률

-78%

지급 비율

BMY 신뢰할 수 있는 배당금을 지급하나요?

BMY 배당 내역 및 벤치마크 참조

예정된 배당금을 받으려면 언제까지 BMY 을 구매해야 하나요?
Bristol-Myers Squibb 배당 날짜
전 배당일	Jul 05 2024
배당금 지급일	Aug 01 2024
전 배당금까지의 일수	4 days
배당금 지급일까지의 일수	31 days

BMY 신뢰할 수 있는 배당금을 지급하나요?

BMY 배당 내역 및 벤치마크 참조

BMY 주식 개요

보상

위험 분석

Bristol-Myers Squibb Company 경쟁사

LSE:GSK

UK£62.4b

NYSE:ZTS

US$79.1b

XTRA:MRK

€67.3b

ENXTPA:SAN

€112.4b

가격 내역 및 성능

최근 뉴스 및 업데이트

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

Recent updates

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024

Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024

Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024

Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial

Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine

Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis

Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept)

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024

U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB).

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)

Bristol-Myers Squibb Company Announces Management Changes

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial

Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)

Bristol Myers Squibb Data At Asco Gu 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers

European Medicines Agency Validates Bristol Bristol-Myers Squibb Company Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic Ros1-Positive Non-Small Cell Lung Cancer and Ntrk-Positive Solid Tumors

Bristol-Myers Squibb Company (NYSE:BMY) entered into definitive merger agreement to acquire RayzeBio, Inc. (NasdaqGM:RYZB) for $3.8 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Bristol-Myers Squibb Company to Report Q4, 2023 Results on Feb 02, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 Commands Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes At Ash 2023

Bristol-Myers Squibb Company Presents New Data At ASH 2023 Demonstrating Clinical Benefit Across B-Cell Malignancies with Breyanzi as A Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol-Myers Squibb Company Announces Phase 3 Checkmate -8Hw Trial Evaluating Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary

Bristol Myers Squibb Announces U.S. Food and Drug Administration Accept the Supplemental Biologics License Application for Opdivo (nivolumab)

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb Appoints Christopher Boerner as Chief Executive Officer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb Company Revises Earnings Guidance for the Full Year 2023

Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 Checkmate -77T Trial

주주 수익률

가격 변동성